Targeting of CYP17A1 Lyase by VT-464 Inhibits Adrenal and Intratumoral Androgen Biosynthesis and Tumor Growth of Castration Resistant Prostate Cancer

Targeting of CYP17A1 Lyase by VT-464 Inhibits Adrenal and Intratumoral Androgen Biosynthesis and Tumor Growth of Castration Resistant Prostate Cancer

Cytochrome P450 17α-hydroxylase/17,20-lyase (CYP17A1) is a validated treatment target for the treatment of metastatic castration-resistant prostate cancer (CRPC). Abiraterone acetate (AA) inhibits both 17α-hydroxylase (hydroxylase) and 17,20-lyase (lyase) reactions catalyzed by CYP17A1 and thus depl...

Full description

Bibliographic Details
Main Authors: Maity, Sankar N., Titus, Mark A., Gyftaki, Revekka, Wu, Guanglin, Lu, Jing-Fang, Ramachandran, S., Li-Ning-Tapia, Elsa M., Logothetis, Christopher J., Araujo, John C., Efstathiou, Eleni
Format: Online
Language:English
Published: Nature Publishing Group 2016
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5066251/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5066251/

Similar Items